Ultraviolet B-induced LGI3 secretion protects human keratinocytes
- Authors
- Lee, Seung Hoon; Jeong, Yun-Mi; Kim, So-Young; Jeong, Hyo-Soon; Park, Kyoung-Chan; Baek, Kwang Jin; Kwon, Nyoun Soo; Yun, Hye-Young; Kim, Dong-Seok
- Issue Date
- Sep-2012
- Publisher
- WILEY-BLACKWELL
- Keywords
- chronic allergic contact dermatitis; H1 receptor antagonist; H4 receptor antagonist
- Citation
- EXPERIMENTAL DERMATOLOGY, v.21, no.9, pp 716 - 718
- Pages
- 3
- Journal Title
- EXPERIMENTAL DERMATOLOGY
- Volume
- 21
- Number
- 9
- Start Page
- 716
- End Page
- 718
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/15156
- DOI
- 10.1111/j.1600-0625.2012.01550.x
- ISSN
- 0906-6705
1600-0625
- Abstract
- Histamine facilitates development of eczematous lesions in chronic allergic contact dermatitis. In addition to the well-known corticosteroid treatments, H1 receptor (H1R) antagonists also have been used. This study observed effects of histamine H4 receptor (H4R) antagonist usage with H1R antagonist in a murine chronic allergic contact dermatitis model, developed by repeated percutaneous challenge to the dorsal skin with 2,4,6-trinitro-1-chlorobenzene (TNCB). The H1R antagonist olopatadine hydrochloride and/or the H4R antagonist JNJ7777120 was then administered. Combination therapy was more effective than H1R antagonist monotherapy. Serum IgE and levels of interleukin (IL)-4, IL-5 and IL-6 (Th2 cytokines) in eczematous lesions decreased with combined therapy. Combined therapy with H1R and H4R antagonists counteracts the disadvantages of each as monotherapeutic agents and potentially represents a new strategy for the treatment of chronic allergic contact dermatitis.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.